Our study demonstrated that the NRG1 protein expression levels increased in response to lapatinib treatment in HER2-overexpressing breast cancer cell lines, and lapatinib could not sustain its inhibition of HER receptor signalling. This evidence concerns the gene ERBB2 and breast cancer.